Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2005

View Archived Issues

Fanesyltransferase inhibitors: potential agents for the treatment of ischemic stroke

Antitumor properties of polyoxomolybdate PM-8 result from induction of apoptosis

U. of South Florida isolates compound from tunicate for melanoma

Solvay advances SLV-308 into phase III

Aptamera shareholders approve acquisition by Antisoma

Enrollment slower than expected in ARIES-1 study of ambrisentan

BLA submission for Procleix West Nile Virus Assay

University of Michigan receives gift for pulmonary fibrosis research

Kyorin completes acquisition of ActivX Biosciences

ANA-975 enters phase I study

Xcyte withdraws phase II/III protocol in chronic lymphocytic leukemia

Antisense Therapeutics reviews progress

Velcade approved for use in Canada

Progen plans new phase II study for PI-88 in combination with DTIC

BMS tests potassium channel opener for urinary incontinence therapy

Bristol-Myers Squibb researchers report synthesis of novel SSRI candidate

Two novel and potent SSRI chemotypes presented by BMS

Preliminary 48-week data on efficacy and safety of tenofovir/emtricitabine regimen in HIV infection

Update on the therapeutic benefits of adalimumab in Crohn's disease

New compositions for controlled release of tolterodine claimed by Ranbaxy

New uses for adiponectin for heart failure described in a patent

New antimitotic agents in early development at SCRAS

Apoptosis inhibitors emerge from research at Vertex

Yamanouchi team identifies new P-selectin inhibitors for coronary artery disease

Scientists at Pfizer report new antiviral agents

Dual muscarinic antagonists/beta2-adrenoceptor agonists for respiratory diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...